|
private:carogen
|
2893268
|
May 23rd, 2019 12:00AM
|
CaroGen Corporation
|
140
|
10.00
|
Open
|
Biotechnology
|
May 23rd, 2019 11:30AM
|
May 23rd, 2019 11:30AM
|
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine.
The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization.
The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.
Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
|
Open
|
vaccines, viral vesicles, biotherapeutics, pharmaceuticals, Hepatitis B, HBV, Colon Cancer, immunotherapy, infectious disease, animal health vaccine
|
Open
|
400 Farmington Ave
|
Farmington
|
Connecticut
|
US
|
06032
|
|
CaroGen
|
|
Pharmaceuticals & Biotechnology
|
|
private:carogen
|
2893268
|
Feb 17th, 2018 12:00AM
|
CaroGen Corporation
|
92
|
12.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine.
The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization.
The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.
Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
|
|
|
|
|
|
|
|
|
|
CaroGen
|
|
Pharmaceuticals & Biotechnology
|
|
private:carogen
|
2893268
|
Feb 16th, 2018 12:00AM
|
CaroGen Corporation
|
92
|
12.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine.
The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization.
The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.
Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
|
|
|
|
|
|
|
|
|
|
CaroGen
|
|
Pharmaceuticals & Biotechnology
|
|
private:carogen
|
2893268
|
Feb 15th, 2018 12:00AM
|
CaroGen Corporation
|
92
|
12.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine.
The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization.
The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.
Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
|
|
|
|
|
|
|
|
|
|
CaroGen
|
|
Pharmaceuticals & Biotechnology
|
|
private:carogen
|
2893268
|
Feb 14th, 2018 12:00AM
|
CaroGen Corporation
|
92
|
12.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine.
The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization.
The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.
Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
|
|
|
|
|
|
|
|
|
|
CaroGen
|
|
Pharmaceuticals & Biotechnology
|
|
private:carogen
|
2893268
|
Feb 13th, 2018 12:00AM
|
CaroGen Corporation
|
92
|
12.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine.
The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization.
The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.
Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
|
|
|
|
|
|
|
|
|
|
CaroGen
|
|
Pharmaceuticals & Biotechnology
|
|
private:carogen
|
2893268
|
Feb 12th, 2018 12:00AM
|
CaroGen Corporation
|
92
|
12.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine.
The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization.
The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.
Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
|
|
|
|
|
|
|
|
|
|
CaroGen
|
|
Pharmaceuticals & Biotechnology
|
|
private:carogen
|
2893268
|
Feb 11th, 2018 12:00AM
|
CaroGen Corporation
|
92
|
12.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine.
The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization.
The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.
Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
|
|
|
|
|
|
|
|
|
|
CaroGen
|
|
Pharmaceuticals & Biotechnology
|
|
private:carogen
|
2893268
|
Feb 10th, 2018 12:00AM
|
CaroGen Corporation
|
92
|
12.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine.
The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization.
The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.
Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
|
|
|
|
|
|
|
|
|
|
CaroGen
|
|
Pharmaceuticals & Biotechnology
|
|
private:carogen
|
2893268
|
Feb 9th, 2018 12:00AM
|
CaroGen Corporation
|
92
|
12.00
|
Open
|
Biotechnology
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine.
The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization.
The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases.
Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
|
|
|
|
|
|
|
|
|
|
CaroGen
|
|
Pharmaceuticals & Biotechnology
|